ISSN 1006-298X      CN 32-1425/R

导航

肾脏病与透析肾移植杂志 ›› 2022, Vol. 31 ›› Issue (5): 485-489.DOI: 10.3969/j.issn.1006-298X.2022.05.018

• • 上一篇    下一篇

供体来源细胞游离DNA在肾移植中的研究

  

  • 出版日期:2022-10-28 发布日期:2022-10-22

Research on donorderived cellfree DNA in kidney transplantation

  • Online:2022-10-28 Published:2022-10-22

摘要: 肾移植是终末期肾病有效治疗手段。移植物损伤是影响移植物存活的主要因素。常用方法如监测血清肌酐、尿蛋白及移植肾活检等,存在迟滞性,不确定性及有创性。供体来源细胞游离DNA(donorderived cellfree DNA,ddcfDNA)是一种源于供体的碎片化、可降解DNA片段。现有研究发现,ddcfDNA在移植肾损伤监测、移植物排斥鉴别、免疫抑制方案调整等方面发挥重要作用,是一种无创、可重复且灵敏度高的新型生物标志物。本文就近年来ddcfDNA在肾移植的研究进展做一综述。


关键词: 供体来源细胞游离DNA, 肾移植, 生物标志物

Abstract: Kidney transplantation is an effective treatment for endstage renal disease. Allograft injury is a major influential factor of allograft survival. Commonly used surveillance methods, such as plasma creatinine, proteinuria, and kidney biopsy, were found to be hysteresis, uncertainty and invasiveness. Donorderived cellfree DNA (ddcfDNA) is a fragmented and degradable DNA fragment derived from transplanted organs. Sudies have shown that ddcfDNA plays a pivotal role in the monitoring of allograft injury, discerning allograft rejection, and guiding immunosuppressant management. As a novel biomarker, ddcfDNA is noninvasive, reproducible and highly sensitive. This article will review the recent research progress on the ddcfDNA in kidney transplantation.


Key words: donor-derived cell-free DNA, kidney transplantation, biomarkers